332 results
DEFA14A
LSTA
Lisata Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
4:53pm
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
DEFA14A
LSTA
Lisata Therapeutics Inc
1 May 23
Additional proxy soliciting materials
4:03pm
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
8-K/A
EX-99.2
q290bl1o09lhta0p1v
4 Oct 22
Other Events
4:42pm
8-K/A
EX-99.1
52vd opvwpu5b
4 Oct 22
Other Events
4:42pm
8-K/A
EX-99.4
1grecuo1n
4 Oct 22
Other Events
4:42pm
8-K
EX-10.1
bxsdvhrxnbf0p87vm
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
425
1r9oodgpa1jzubp1rtdv
2 Sep 22
Business combination disclosure
4:01pm
425
h8516u jwsbx02i2k
15 Aug 22
Business combination disclosure
6:46am
425
hhm 6p8zwpb
10 Aug 22
Business combination disclosure
8:08am
8-K
EX-99.1
zb5mxvfxa94uk85
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.3
9lw5bxzbv3o zao
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
424B3
vw1ous9o2vr30xjj4ly9
29 Jul 22
Prospectus supplement
4:06pm
425
c17fibmg4bj77cky1
6 Jul 22
Business combination disclosure
4:05pm